Editorial
|
|
|
A two-way exchange of information
|
|
|
Marketing Authorisations
|
|
|
A "me-too" of the dangerous dapagliflozin
|
|
|
|
|
|
Defective urea synthesis: a welcome formulation
|
|
|
|
|
|
Decisive in some hereditary bile acid deficiencies
|
|
|
|
|
|
|
Prolonged survival in Philadelphia chromosome-positive cases
|
|
|
|
|
|
|
No proven advantages but many uncertainties
|
|
|
Adverse Effects
|
|
|
Psychotropics, sugar-containing medicines, etc.
|
|
|
|
|
|
|
Results of a survey in a maternity clinic
|
|
|
|
|
|
|
Sometimes the same drug and same adverse effects
|
|
|
|
Reviews
|
|
|
First-choice treatments
|
|
|
|
Outlook
|
|
|
Part 2: From spontaneous reports to agency reviews and decisions
|
|
|
|
|
|
|
Reduction of exposure in children and pregnant women is essential
|
|
|
|